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THE EMOTIONAL HEART 
Abstract 
Cardiovascular disease (CVD) and depression worldwide are societally and economically 
costly. The broader literature now recognises depression as a key risk factor in CVD 
populations, leading to the implementation of screening recommendations in this high-risk 
cohort. However, these guidelines did not include anxiety. A growing body of literature is 
now acknowledging an important role for anxiety as a potential CVD modifiable risk factor. 
Here we briefly summarise the supporting evidence in regards to the research on depression, 
anxiety and CVD and we discuss the forgotten notion of comorbidity and its potential 
influence on CVD risk and depression treatment outcomes. Lastly, we discuss the potential 
for psychiatric theory pertaining to anxiety and depression comorbidity to inform screening 
procedures in CVD patients. Lastly, we discuss the clinical implications in regards to the 
proposed method with specific recommendations for future research.        
Keywords: depression, anxiety, cardiovascular disease, comorbidity, hierarchical theory, 
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The statistics on cardiovascular disease (CVD) (e.g., coronary heart disease (CHD), heart 
failure (HF), coronary artery disease (CAD), Ischemic Heart Disease (IHD)) reflect opposing 
trends. On the one hand, the mortality rates from CVD in Australia have decreased from 20% 
of deaths in 2001 to 15% of deaths in 2011 (Australian Institute of Health and Welfare 
(AIHW), 2014). On the other hand, CVD affects one in six accounting for more than 4.2 
million people Australia wide (Australian Bureau of Statistics (ABS), 2015). The number of 
CVD related hospital admissions has increased by 8% in 10 years (AIHW, 2016) and 1.4 
million people are prevented from living a full life because of a CVD related disability (ABS, 
2015). Thus, CVD still remains one of the world’s leading health problems and one of the 
biggest burdens on our economy. With a rise in the average life expectancy and prevalence of 
cardiovascular risk factors (e.g. obesity), increases in economic and societal costs, and 
decreases in quality of life seem probable as CVD patients live longer (Pandya, Gaziano, 
Weinstein, & Cutler, 2013).      
DEPRESSION IN CARDIOVASCULAR DISEASE 
Psychiatric disorders are particularly relevant to CVD (Correll et al., 2017). Major 
depression, a condition characterised by more than 2 weeks of depressed mood or loss of 
pleasure and multiple somatic symptoms (e.g., abnormalities in sleep, energy, concentration, 
appetite, and/or psychomotor functioning) (American Psychiatric Association,  2013), has 
received the most attention in CVD. Research popularity concerning depression in CVD is on 
the grounds that approximately 20% of CHD patients meet criteria for major depression after 
a heart attack, or, after undergoing coronary artery bypass graft surgery (Tully & Baker, 
2012). Though, prevalence rates increase if milder forms of depression are considered. Given 
the high prevalence rates of depression in women than men in the general population, not 
surprisingly, self-reported symptom severity rates are somewhat higher in women (30.6%) 
than in men (19.8%) (Pogosova et al., 2017). Depending on the degree of functional 
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impairment, depression is also prevalent in roughly 20% of patients with chronic HF 
(Rutledge, Reis, Linke, Greenberg, & Mills, 2006). From a clinical perspective, it is now 
generally accepted that one in five patients with CHD, or, HF is depressed, a figure three 
times that found in the general population (Kessler et al., 2003).  
DEPRESSION AND RISK OF CARDIOVASCULAR DISEASE  
A consistent body of literature now supports the view that depression is a risk factor for 
developing CVD. Rugulies (2002), and Wulsin and Singal (2003) reported that depressed 
patients had a 60% higher chance of developing CHD. Further, those with clinical depression 
tended to have a higher risk (relative risk=2.69; 95%; CI: 1.63-4.43) of developing heart 
disease than those with non-clinical depression (relative risk=1.49; CI: 1.16-1.92) 
demonstrating a dose-response relationship. Not surprisingly, depression in CHD has a 
population attributable risk (PAR) comparable to smoking, and higher than diabetes (PAR: 
9.9%) and hypertension (PAR: 17.9%)(Yusuf et al., 2004). Rates as high as 80-90% were 
reported by Nabi et al. (2010); Nicholson, Kuper, and Hemingway (2006). Though, 
Nicholson et al. (2006) concluded that a failure to adjust for known CVD risk factors in many 
of the studies likely resulted in inflated estimates. For example, when adjusting for known 
cardiovascular risk factors (e.g., left ventricular function), the relative risk dropped by half 
(Nicholson et al., 2006). A recent meta-analysis reported more conservative findings, in that 
depression (i.e., meeting diagnostic criteria, or, achieving a higher questionnaire score), had 
roughly a 30% greater risk of heart attack and heart attack (Gan et al., 2014). Even when 
excluding angina and other non-definitive CHD outcomes, depression is associated with a 
1.31 (95%CI, 1.09–1.57) and 1.36 (95%CI, 1.14–1.63) for heart attack and coronary death, 
respectively (Wu & Kling, 2016). While self-reported depression appears to increase the risk 
of incident CVD by four-fold when compared to other physically healthy people (Kyrou et 
al., 2017), the rates are still alarming when focusing on those with diagnosed severe mental 
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illnesses. For example, in a large scale meta-analysis major depressive disorder was 
significantly associated with CVD (odds ratio: 1.75, 95%CI: 1.36-2.26, p = 0.001) and CHD 
(odds ratio: 2.52, 95%CI: 1.81-3.52, p <0.001) (Correll, 2017).  Little attention has been paid 
to whether different subtypes of depression (i.e. melancholic, psychotic, atypical or 
undifferentiated) significantly moderate CVD risk, though, there is some evidence that those 
with atypical major depression or double depression (i.e., major depressive disorder and 
dysthymia) may be a subgroup that is particularly at high risk of new-onset CVD (Case, 
Sawhney, & Stewart, 2018). Further, those who have never been depressed before appear to 
have different risk factors and a more severe state of CVD as opposed to pre-existing or 
recurrent depression (de Jonge, van den Brink, Spijkerman, & Ormel, 2006; Goodman, 
Shimbo, Haas, Davidson, & Rieckmann, 2008; Grace et al., 2005; Spijkerman et al., 2005).        
In addition to being a risk factor for the development of CVD, depression is also predictive of 
worse outcomes following cardiovascular events. Nancy Frasure-Smith, Lespérance, and 
Talajic (1993) were one of the first to document this relationship in patients following a heart 
attack where the six-month mortality of depressed patients was 17%, corresponding to almost 
4 (95%CI: 2.25-4.63) times the increased risk compared to non-depressed patients. Since then 
a number of meta-analyses have evaluated all-cause, or, cardiac-related mortality after a heart 
attack, or, acute coronary syndrome (Barth, Schumacher, & Herrmann-Lingen, 2004; A 
Meijer et al., 2013; Meijer et al., 2011; Nicholson et al., 2006; Van Melle et al., 2004). All 
studies yielded comparative findings in that depression was predictive of all-cause mortality, 
cardiac-related mortality, and/or a combined endpoint of all-cause mortality and cardiac 
morbidity (Carney & Freedland, 2016). According to the largest of the meta-analysis, patients 
with post-heart attack depression have a nearly three-fold increased risk for cardiac mortality 
and nearly two-fold risk for new cardiac events (Meijer et al., 2011). This increased risk of 
mortality and secondary events is also true in HF (Rutledge et al., 2006). Even when 
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adjusting for known risk factors using the Global Registry of Acute Coronary Events 
(GRACE), a highly predictive measure of cardiac outcomes following a cardiac event (Fox, 
Eagle, Gore, Steg, & Anderson, 2010), depression still remained an independent predictor of 
all-cause mortality, and fatal and non-fatal cardiac events.   
In a dose-response fashion, the severity of depression also appears to predict cardiovascular 
outcomes (Fiedorowicz, 2014; Wulsin et al., 2005). In a study reporting depression as a 
predictor of outcome following heart attack, compared to those with a Beck Depression 
Inventory (BDI) score lower than five, hazard ratios (HR) were highest for BDI scores 
exceeding 18 (HR. ) and lowest for scores between 5-9 (HR 1.4) (Lespérance, Frasure-Smith, 
Talajic, & Bourassa, 2002). Despite these findings, depression is a chronic, fluctuating 
condition and single measures do not provide sufficient information on the course of this 
condition over time (Freedland & Carney, 2013; Palacios, Khondoker, Mann, Tylee, & 
Hotopf, 2018). Further, evidence suggests clinicians should be aware of the aversive 
prognostic effects of somatic/affective depressive symptoms compared to cognitive/affective 
depressive symptoms (de Miranda Azevedo, Roest, Hoen, & De Jonge, 2014; Freak‐Poli, 
Ikram, Franco, Hofman, & Tiemeier, 2018). In HF, worsening somatic symptoms, but not 
cognitive-affective symptoms, were found to be independently associated with increased 
mortality (Hwang, Moser, Pelter, Nesbitt, & Dracup, 2015).  
Finally, in addition to the poor survival rate and increased risk of further CVD events, 
depression is also a significant predictor of decline in overall health status over time. In a 
study of 960 outpatients with CHD, depression predicted decline of health status across a five 
year period (Sin, Yaffe, & Whooley, 2015), while depressive symptoms have also been found 
to predict health care costs over time. Palacios et al. (2018) used Latent Class Growth 
Analysis (LCGA) to identify five distinct depression symptom trajectories ‘stable low’, 
‘chronic high’, ‘improving’, ‘worsening’, and ‘fluctuating’ based on the Hospital Anxiety and 
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Depression Scale (HADS). CHD patients in the ‘chronic high’ class had average costs 
approximately double that of a patient in the ‘stable low’ class.  
MENTAL HEALTH SCREENING IN CARDIOVASCULAR DISEASE   
Given the aforementioned, it is not surprising that routine screening for depression is now 
recommended by the American Heart Association (AHA)(Lichtman et al., 2008). The AHA 
recommends screening patients using the two-item Patient Health Questionnaire (PHQ-2) 
(Lichtman et al., 2008). A response of ‘yes’ to one of the two questions yields 90% 
sensitivity and 70% specificity for a diagnosis of depression (McManus, Pipkin, & Whooley, 
2005). Following a score of one or higher on the PHQ-2, the AHA suggests that all nine 
items on the PHQ are administered to the patient. A score of above 10 showed a sensitivity 
and specificity of 88% for a diagnosis of major depression (Kroenke, Spitzer, & Williams, 
2001).  
Interestingly, anxiety was not considered in the AHA recommendations despite the fact that 
disorders of excessive fear and anxiety constitute the most prevalent psychiatric disorders in 
western countries, with the highest lifetime prevalence estimates ranging from 14%-29% 
(Kessler et al., 2005). Anxiety (i.e., the anticipation of future threat) is also highly prevalent 
in CVD populations. In a large European epidemiological study of 7589 patients who 
experienced a CHD event, approximately 1.4 years after the event, 26.3% of participants had 
symptoms of anxiety as measured by the Hospital Anxiety and Depression Scale-Anxiety 
subscale (HADS-A) (Pogosova et al., 2017). Other prevalence rates vary considerably 
depending on CVD subtype. For example, the pooled prevalence of anxiety symptoms is 
approximately 28% in HF patients (Easton, Coventry, Lovell, Carter, & Deaton, 2016), 27% 
following a heart attack, (Daniel et al., 2018), 20-40% following a cardioverter defibrillator 
implantation (Magyar-Russell et al., 2011), and 25% before coronary artery bypass graft 
surgery (Geulayov, Novikov, Dankner, & Dankner, 2018). Importantly, the prevalence of 
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anxiety remained consistent one year following the surgery. Similarly, three years following 
percutaneous coronary intervention anxiety symptoms were as high as 32%, after controlling 
for participant age and smoking habit (p <0.001) (Olsen, Schirmer, Wilsgaard, Bønaa, & 
Hanssen, 2018). Lower estimates are reported by prospective studies using structured clinical 
interviews that provide psychiatric diagnoses. For example, the point prevalence rate of any 
anxiety disorder in CHD is approximately 16% in CHD (Tully, Cosh, & Baumeister, 2014) 
and 13% in HF(Easton et al., 2016). Thus, anxiety disorders are as common as a unipolar 
depressive disorder in CVD (Celano, Suarez, Mastromauro, Januzzi, & Huffman, 2013; 
Tully, Harrison, Cheung, & Cosh, 2016). Generalized Anxiety Disorder (GAD) is the most 
common anxiety disorder with an 11% point prevalence and 26% lifetime prevalence of 
GAD in CHD patients (Tully & Cosh, 2013). This is also consistent with prevalence rates of 
GAD in HF (Easton et al., 2016). Panic disorder is also common in CHD with one paper 
reporting prevalence rates up to 50% (Fleet, Lavoie, & Beitman, 2000). However, given that 
panic has been found to be significantly less common in post-acute coronary syndrome 
populations than GAD, and depression, lower estimates of 5-8% reported by Celano et al. 
(2013); Todaro, Shen, Raffa, Tilkemeier, and Niaura (2007) are likely more realistic. 
Importantly, anxiety disorder prevalence fluctuates depending on demographics, study 
design, and the setting (i.e. inpatient or outpatient) (Tully et al., 2014). Making an anxiety 
disorder diagnosis in chronic illnesses is not straightforward due to somatic symptom 
overlaps, such as those existing in panic disorder (e.g., chest pain and heart palpitations), and 
the clinical presentation of some CVDs, such as CHD (Tully et al., 2015). Taking this into 
consideration, it is not surprising that there is still considerable deliberation in regards to the 
strength of the relationship between panic disorder and CHD (Katerndahl, 2008). Notably, 
CHD and HF symptoms also significantly overlap with depression (Smolderen et al., 2009), 
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and therefore, depression is not exempt from the consequences of somatic symptoms 
confounding psychiatric disorder diagnoses.    
Despite the high prevalence of anxiety disorders in CVD populations, anxiety screening is 
relatively uncommon, and as such it often goes undetected and untreated in cardiac 
populations (Cully, Jimenez, Ledoux, & Deswal, 2009; Hurley et al., 2017; Polikandrioti et 
al., 2015).  For example, Huffman et al. (2006) reported that following admission for a heart 
attack health care providers failed to identify anxiety disorders in up to 50% of the patients 
and 69% with elevated symptoms of anxiety. Patients with anxiety symptoms are also rarely 
followed up. One study reported that a third of acute coronary patients with raised anxiety 
levels reported not being followed up by medical professionals in regards to these symptoms 
over 12 months (Grace, Abbey, Irvine, Shnek, & Stewart, 2004). Currently, if anxiety 
screening is performed, its recommend that patients are evaluated during a period of relative 
clinical stability to avoid false positive anxiety screens from those with subclinical symptoms 
of psychological distress that are often experienced in response to a cardiac event (Celano et 
al., 2015). More recently the AHA has recommended that more research needs to be 
published investigating whether anxiety disorders contribute independently to CHD 
prognosis (Lichtman et al., 2014). 
ANXIETY AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE 
As per the AHA recommendations, there has been a rapidly growing number of empirical 
papers evaluating anxiety as a key risk factor in CVD (Janszky, Ahnve, Lundberg, & 
Hemmingsson, 2010; Nabi et al., 2010; Seldenrijk et al., 2015; Tully et al., 2015). Restricting 
their analysis to CHD only, Roest, Martens, de Jonge, and Denollet (2010) showed that in 
250,000 patients, with follow up periods ranging from 2-20.9 years, the increased risk of 
CHD in people with anxiety was 26% and 48% for cardiac death. Despite these findings, 
multivariable analysis revealed that only 10 studies from a total of 20 demonstrated a 
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significant relationship between any anxiety disorder and CHD, highlighting limitations in 
regards to the heterogeneity of the findings concerning this relationship (Celano, Daunis, 
Lokko, Campbell, & Huffman, 2016). An extension of this work included a further 8 studies 
to also investigate the risk of any anxiety disorder with HF and cardiovascular mortality. 
Anxiety disorders were associated with a 41% increased risk of CHD and cardiovascular 
mortality, and a 35% increased risk of HF (Emdin et al., 2016). However, again, these 
findings are questionable given the lack of adjustment for confounding factors. Given the 
high rates of comorbidity (Kessler et al., 2008), adjusting for depression is crucial in order to 
ascertain whether anxiety is a true risk factor independent of depression. Taking this 
relationship into consideration, a recent meta-analysis with a total of 37 studies, with 
1,565,699 participants found that anxiety (including both symptoms and disorders) was 
associated with a 52% increased risk of CVD incidence independent of traditional risk factors 
and depression (Batelaan, Seldenrijk, Bot, Van Balkom, & Penninx, 2016) . The researchers 
concluded that the effects of anxiety and depression are comparable and that the depression 
risk ratios reported by Nicholson et al., (2006) may be the result of a failure to adjust for 
anxiety as an important covariate.  
Analysing anxiety disorder subtypes has uncovered differential associations with CVD. After 
adjusting for depression, Edmondson, Kronish, Shaffer, Falzon, and Burg (2013) found that 
people with PTSD had a 27% increased risk for incident CHD and cardiac-specific mortality, 
while household interviews conducted in 52 095 study participants in 19 countries found that 
diagnoses of depression, panic disorder, specific phobia, and posttraumatic stress disorder 
were all associated with self-reported heart disease onset (OR=1.3–1.6) (Scott et al., 2013). 
While GAD was not in these findings, the NEMESIS study based on 5149 persons at risk of 
cardiac diseases found that GAD was most strongly associated with the onset of non-fatal 
CVD in a three year follow up (Batelaan, ten Have, van Balkom, Tuithof, & de Graaf, 2014). 
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However, over a six year follow up, Seldenrijk et al. (2015) found that panic disorder was the 
only anxiety disorder associated with CVD incidence. Tully et al., (2015) conducted a meta-
analysis to clarify the extent to which panic disorder offers risk in regards to the development 
of CHD. A total of 1,131,612 people with 58,111 cardiac events across 12 studies revealed 
that people with panic disorder were 47% more likely to have CHD, 36% more likely to 
suffer a heart attack, and 40% more likely to have a major adverse cardiac event (Tully et al., 
2015). Panic disorder was also associated with other adverse cardiovascular events, including 
death from CAD, sudden cardiac death, and acute heart attack (fatal and non-fatal).  Despite 
the robustness of the study, given that panic symptoms substantially overlap with those of 
cardiac disease, the researchers could not rule out whether panic symptoms were the result of 
an undetected cardiac illness. Collectively, the findings above demonstrate that it is still 
largely inconclusive exactly which anxiety subtypes are associated with incident CVD in 
previously non-diseased persons (Tully, 2017). 
ANXIETY IN ESTABLISHED CARDIOVASCULAR DISEASE 
In addition to being a risk factor for the development of CVD, the extant literature suggests 
that anxiety predicts poorer prognosis in persons with already established cardiac disease. 
While controlling for disease severity, anxiety, but not depression, measured one month 
following hospital discharge was an independent predictor of recurrent heart attack or cardiac 
death in post-heart attack patients (Strik, Denollet, Lousberg, & Honig, 2003), while patients 
with elevated anxiety symptoms in the coronary care unit were also found to exhibit greater 
mortality within the first year after a heart attack (Wrenn, Mostofsky, Tofler, Muller, & 
Mittleman, 2013). Meta-analytic work has also confirmed that anxiety was associated with a 
36% increased risk of adverse cardiac outcomes, 47% risk of all-cause mortality, 23% risk of 
cardiac mortality, and a 71% risk of new cardiac events after a heart attack (Roest, Martens, 
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Denollet, & De Jonge, 2010). However, it is not clear the extent to which the association was 
independent of depression.  
Similar findings exist in stable heart disease where a 2-fold increased risk of adverse CVD 
events was reported in a rehabilitation sample (Rothenbacher, Hahmann, Wüsten, Koenig, & 
Brenner, 2007), and in patients with elevated anxiety during hospitalisation for cardiac 
catheterisation (Watkins et al., 2013), while patients with increasing anxiety at 12 months 
follow up had a significantly higher risk of poor cardiac outcomes when compared to patients 
with consistent anxiety over time (Shibeshi, Young-Xu, & Blatt, 2007). Anxiety also predicts 
hospitalisations in patients with chronic HF (Vongmany, Hickman, Lewis, Newton, & 
Phillips, 2016). Finally, in a meta-analysis of 44 studies, anxiety was associated with an 
increased risk of cardiac events and death in patients with established CAD. Despite these 
findings, the reported risk was attenuated when controlling for covariates leaving the 
researchers to conclude that the relationship is not as strong as depression (Celano et al., 
2015). 
In regards to specific anxiety disorder diagnoses, evidence suggests that GAD increases the 
risk for major cardiac events (Frasure-Smith & Lespérance, 2008; Martens et al., 2010; Tully 
et al., 2011). In Martens et al. (2010), after adjustment for demographic characteristics, 
comorbid conditions (including major depressive disorder), cardiac disease severity, and 
medication use, GAD remained associated with a 62% higher rate of cardiovascular events 
(hazard ratios: 1.62; 95%CI: 1.11-2.37; p = .01). Similarly, over a 10 year follow up period, 
Roest, Zuidersma, and de Jonge (2012) reported that GAD was associated with an increased 
rate of cardiac events independent of depression and disease severity, while patients meeting 
criteria for GAD (not panic disorder), prior to CABG surgery had an increased risk of 
cardiovascular and cerebrovascular outcomes five years later (Tully et al., 2015). 
Interestingly, some studies reported no association of GAD in established CVD (Versteeg et 
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al., 2013), while some even report GAD as a protective factor (Parker, Hyett, Hadzi-Pavlovic, 
Brotchie, & Walsh, 2011). Collectively, there is a paucity of studies evaluating anxiety 
subtypes in CHD suggesting more high-quality studies are needed (Tully, Cosh, & 
Baumeister).   
COMORBIDITY OF ANXIETY AND DEPRESSION 
There are several issues to consider in understanding the relationship between anxiety and 
CVD, including that anxiety rarely exists in isolation. While there appears to be an 
independent association of depression and anxiety in CVD, many of the studies did not take 
into consideration comorbidity, despite the likelihood of many depressed persons having a 
comorbid anxiety disorder (Kessler et al., 2008). GAD and major depression are considered 
the most common type of anxiety-mood comorbidity (Gorwood, 2004). Research in CVD 
yields comparative findings. For example, in established CHD, up to half of the patients were 
considered to have comorbid depression and anxiety (Tully et al., 2014), while Denollet and 
colleagues (2006) report that mixed anxiety and depressive symptom profiles are much more 
common after a heart attack than depression alone. In 4,256 participants from the Vietnam 
Experience Study, 55% of those with major depression also had GAD (Phillips et al., 2009). 
Similarly, in 2,315 participants in the Netherlands Study of Depression and Anxiety, 
approximately 40% had comorbid depression and anxiety disorders (Vogelzangs et al., 2010).  
While some studies do not agree (Frasure-Smith & Lespérance, 2008), there is now building 
evidence to suggest that the combined impact of depression and anxiety in cardiac 
populations results in poorer outcomes in CVD. For example, in the Vietnam Experience 
Study, veterans with comorbid major depression and GAD were at a substantially greater risk 
of mortality than the veterans who reported either condition alone (Phillips et al., 2009). The 
co-occurrence of anxiety and depression also increased the risk of hospitalisations when 
compared to either alternate disorder (Chamberlain, 2011), while in stable heart disease 
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patients the combined presence of anxious and depressive symptoms contributed significantly 
to mortality, whereas, anxiety and depression alone did not (OR 2.35, 95% CI 1.23–4.47, 
p=.010) (Doering et al., 2010). Further, the findings of  Watkins et al. (2013) reported a 
three-fold increased risk of mortality in patients with comorbid anxiety and depression in 
CHD, higher than that revealed for either factor alone, while the same was reported for the 
combined effects of anxiety and depressive symptoms on the mortality rate of adults with HF 
(Alhurani et al., 2015).  
Recently it was reported that patients with depressive symptoms in HFare at a high risk for 
experiencing anxiety symptoms, also, and therefore, they encourage clinicians to assess 
patients for comorbidity (Easton et al., 2016). Particularly since, in groups of depressed 
populations without co-occurring medical illnesses, the presence of anxiety is associated with 
a slower response to antidepressants (Altamura, Montresor, Salvadori, & Mundo, 2004), less 
symptom reduction over time (Altamura et al., 2004), non-adherence to treatment, and a 
poorer overall response to intervention (Howland et al., 2008; Rush et al., 2008). In a CVD 
population higher levels of anxiety symptoms as measured by the HADS-A were found to be 
associated with less improvement of depressive symptoms from baseline and increased odds 
of depression persistence at 6 months, independent of functional status, baseline depression 
severity, and history of depressive episodes (Celano et al., 2012).  Similarly, anxiety 
evaluated within 2 weeks of an acute coronary syndrome was significantly associated with a 
depressive disorder at follow up and less improvement in depressive symptoms over 1 year 
(Kim et al., 2017).  Collectively, these findings highlight the importance of identification and 
management of anxiety as a way of optimising depression interventions and decreasing the 
patient’s overall risk of adverse CVD outcomes.  
HIERARCHICAL THEORY OF COMORBIDITY 
THE EMOTIONAL HEART          21 
 
Psychiatric theory has attempted to provide explanations for the high rates of anxiety and 
depression comorbidity. Such theoretical observations have the potential to provide ways in 
which comorbid disorders could be detected more effectively in high risk CVD populations. 
For example, factor analytic work focused on understanding relationships among mental 
disorders has shown that the most common psychological disorders can be explained in a 
hierarchical fashion with an overarching general factor (i.e., a predisposition to experience 
negative affect, such as sadness, anger, disgust, or fear; Watson, 2005) and two sub-domains: 
‘internalising’ and ‘externalising’ (see Figure 1), where, notably, depression and anxiety 
disorders load onto the ‘internalising’ domain (Kotov et al., 2017; Krueger & Markon, 2006). 
This two-factor structure has been found to be robust and various studies continue to support 
this idea (Kotov et al., 2017). For example, in comorbidity studies the two domains have been 
found to match comorbidity patterns observed across an individual’s lifetime (Kessler, 
Petukhova, & Zaslavsky, 2011). In addition,  the two major dimensions have also been 
accounted for in genetic studies (Kendler et al., 2011).  The two-factor structure is also 
considered to be structurally stable across countries (de Jonge et al., 2018).  
However, as further structural analytic work reveals, the two-factor structure is more complex 
with the existence of multiple sub diversions (Kotov et al., 2017). For example, disorders 
under the ‘internalising’ domain tend to cluster together forming lower order groups, two of 
which are, ‘anxious-misery’ (i.e., major depressive disorder, dysthymia, generalised anxiety 
disorder and post-traumatic stress disorder), and ‘fear’ (i.e., panic disorder, agoraphobia, 
specific phobia, social anxiety disorder and obsessive-compulsive disorder (OCD)) (Kotov et 
al., 2017; Krueger, 1999). Notably, GAD is considered more strongly related to the unipolar 
disorders than to the other anxiety disorders since it shares more of the general factor 
variance (i.e., trait disposition towards negative affectivity). While there is some debate 
regarding the structure of the lower order, the two-factor structure is considered robust 
THE EMOTIONAL HEART          22 
 
(Kotov et al., 2017), and is a partial explanation for the substantial interrelation of anxiety 

















Figure 1. Flowchart of the Hierarchical Taxonomy of Psychopathology. Adapted from Kotov et al., 
(2017). AG = Agoraphobia; SAD = Social Anxiety Disorder; Panic = Panic Disorder; OCD = 
Obsessive-Compulsive Disorder; PTSD; Post-traumatic Stress Disorder; GAD = Generalized Anxiety 
Disorder; ADHD = Attention Deficit Hyperactivity Disorder; PD = Personality Disorder   
Inopportunely, such observations that inform psychiatric and psychological nomenclature are 
rarely employed in the screening of mental health in CVD. Anxiety disorders, as single 
constructs, are only just beginning to attract attention in screening studies and very few 
studies have discussed recommendations for the screening of anxiety and depression 
contemporaneously (Bunevicius et al., 2013; Celano et al., 2013). Bunevicius and colleagues 
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reported on three self-report measures to detect anxiety disorders in a CAD sample. A notable 
finding was that depression screening omitted a substantial number of persons suffering from 
an anxiety disorder, demonstrating that disorder-specific screening is invaluable in CVD 
populations where there is high risk and comorbidity is likely to exist. The researchers 
recommended further investigation into the inclusion of anxiety screening as a compliment to 
depression screening. Celano et al. (2013) also concluded that the screening of both 
depression and GAD (but not panic disorder) is justified in CVD, given the high prevalence 
rates of major depression and anxiety (GAD) in their sample (20.5% and 18.5%, 
respectively). The researchers advocated for the use of the amalgamation of the Patient 
Health Questionnaire – two item and the Generalized Anxiety Disorder – two-item scales 
given they could be performed in a timely matter. However, a confirmation diagnosis would 
need to be completed via the PHQ-9 and GAD-7 items, in a two-step process. Although this 
recommendation takes into consideration two highly comorbid and prevalent disorders in 
CVD, there is potential for other disorders to coexist that may not be captured by this method. 
Though this is yet to be empirically tested in a CVD population, the theoretical ‘clusters’ may 
solve the comorbidity quandary by targeting the common factors (i.e., ‘anxious-misery’ or 
‘fear’) that contribute to the emotional disorders. Given that a psychometrically sound 
instrument could be tested and employed to target ‘anxious-misery’ and ‘fear’ clusters, this 
would also simplify the screening process and the need for multiple screening measures 
recommended by Bunevicius et al. (2013) and Celano et al. (2013).  
CLINICAL IMPLICATIONS AND FUTURE RESEARCH 
Detecting psychological distress in patients with CVD is only the first step in coordinating 
the best care of such patients, and screening that is not interlinked with a treatment plan is 
likely not efficacious for the patient. Indeed, the recommendation from the AHA in regards to 
the screening of depression in CHD has since been challenged as there remains a paucity of 
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studies demonstrating that it is useful and cost-effective in improving outcomes for heart 
disease patients (Hasnain, Vieweg, Lesnefsky, & Pandurangi, 2011; Thombs et al., 2008; 
Thombs et al., 2013; Ziegelstein & Thombs, 2011). A review concluded that treatments that 
are deemed suitable for this cohort are only considered modestly effective (Carney & 
Freeland, 2017). The lack of encouraging outcomes in treatment studies has led some to 
question whether, therapeutically, depression is a suitable target in CVD, indicating the need 
to search beyond the realms of depression to improve outcomes for patients. There is 
evidence to suggest that potential therapeutic efficacy may lie within transdiagnostic methods 
that target the core processes common to the emotional disorders. A study that examined the 
specific effect of treatment on comorbid anxiety and mood diagnoses, found that after using a 
transdiagnostic method, 66.7% of the participants with comorbidity at baseline did not meet 
criteria for a comorbid diagnosis compared to 48.5% where only the main diagnosis was 
targeted (Norton et al., 2013). In CVD, the use of collaborative care programs, and 
interdisciplinary treatment approaches are also yielding promising results (Bradley & 
Rumsfeld, 2015). The following findings indicate that cluster based screening can also be 
linked to treatment plans that may increase treatment efficacy for depression and anxiety in 
this population. However, to date, there is a paucity of empirical research suggesting that the 
theoretical ‘clusters’ could inform screening procedures in CVD populations (Tully & 
Penninx, 2012), and thus further research is warranted. 
SUMMARY AND CONCLUSIONS 
The prevalence and risk of depression in CVD are fairly established in the broader literature 
leading to the recommendation that depression should be screened in this high-risk cohort. 
While it may have been slow to start, there is now a growing body of evidence to indicate 
that anxiety is also associated with some increased risk of incident CVD and also, in those 
with already established conditions. Despite evidence for their independent roles, anxiety and 
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depression rarely exist in isolation. As such, there are apparent limitations to screening 
depression as a lone construct, including implications for CVD related risk and the efficacy 
of interventions. The theoretical ‘clusters’ may provide an answer to the comorbidity 
quandary, as well as facilitate a shift from disorder-specific interventions to include 
transdiagnostic methods that may also increase treatment efficacy in CVD. However, the 
paucity of studies evaluating this novel approach to screening suggests this warrants further 
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Abstract 
To examine the utility and diagnostic detection of common anxiety and depression 
instruments for the screening of internalising ‘clusters’ (i.e., anxious-misery and fear) in a 
cardiovascular population. The participants, patients with a hospital administration for 
cardiovascular disease (CVD) (n = 85, 59 (69.4%) were male), underwent a structured 
clinical interview with the MINI- International Neuropsychiatric Interview. The participants 
also completed the Patient Health Questionnaire (PHQ) 9 item scale, Generalized Anxiety 
Disorder (GAD) 7 item scale, Overall Anxiety Severity Impairment Scale (OASIS), and the 
stress subscale of the Depression Anxiety Stress Scale (DASS). The PHQ-9 (sensitivity, 
85.71%, specificity 82.94%), and the GAD-7 (sensitivity 85.71%, specificity 82.81%) 
yielded appropriate screening properties for the ‘anxious-misery’ cluster. The GAD-7 was the 
only instrument to display favourable screening properties for the ‘fear’ cluster (sensitivity 
81.25%, specificity 76.81%). The PHQ-9 and the GAD-7 can be implemented to reliably 
screen emotional disorder ‘clusters’ in a CVD population.   
Keywords: depression, anxiety, internalising disorders, clusters, receiver operating 
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Depression and anxiety (e.g., collectively named the emotional disorders) are highly 
prevalent (29% anxiety disorders; 19% depressive disorders) and disabling resulting in 
substantial individual, societal and economic cost worldwide (Chisholm et al., 2016). Their 
coexistence is also common and alarming, both in clinical and community samples, and 
concurrently and across the lifespan (Brown, Campbell, Lehman, Grisham, & Mancill, 2001; 
Hasin & Kilcoyne, 2012; Kessler, Chiu, Demler, & Walters, 2005; Teesson, Slade, & Mills, 
2009). Some scholars implicate the current diagnostic classification system in the high rates 
of comorbidity between depression and anxiety (Zbozinek et al., 2012), other evidence is 
found in twin studies where genetic risk factors for depression and anxiety substantially 
overlap in men and women (Kendler, Gardner, Gatz, & Pedersen, 2007; Kendler, Neale, 
Kessler, Heath, & Eaves, 1992), while some have suggested that depression and anxiety share 
underlying metacognitive processes and beliefs (Hendriks et al., 2014; Rector, Szacun-
Shimizu, & Leybman, 2007; Wells & Matthews, 1994). Although, this is yet to be 
empirically tested. Other evidence exists in intervention studies where treatments for one 
disorder effectively reduce symptoms in the other, such as psychotherapy (Weitz, Kleiboer, 
van Straten, & Cuijpers, 2018), or, antidepressant intervention (Andrews et al., 2009).  
Structural modelling research suggest that a common ‘negative affectivity’ component, a 
general dimension of subjective distress including negative emotional states such as fear, 
anger, sadness, guilt, and disgust (Watson, 2005)), is an etiological factor partially 
responsible the high rates of comorbidity (Kotov, Gamez, Schmidt, & Watson, 2010). 
Though ‘negative affectivity’ is considered to be common to all emotional disorders, its 
disposition failed to account for heterogeneity across disorders, and the broader literature 
now supports a structure that is far more complex (Kotov et al., 2017). For example, 
supporting a ‘clustering’ approach, structural modelling suggests that common mental 
disorders tend to band together under broader domains. In particular, the emotional disorders 
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were found to cluster under the ‘internalising’ domain, which is distinct from the 
‘externalising’ domain reflecting the antisocial and substance use disorders (Kotov et al., 
2017; Krueger & Markon, 2006). Subsequent research suggested that the ‘internalising’ 
domain can bifurcate into lower order groups characterised by ‘anxious-misery’ (e.g., Major 
Depressive Disorder, Dysthymia, Generalized Anxiety Disorder (GAD), and Post Traumatic 
Stress Disorder (PTSD)), or, by ‘fear’ (e.g., Panic Disorder, Agoraphobia, Specific Phobia, 
Social Anxiety Disorder, and OCD) (de Jonge et al., 2018; Eaton et al., 2013; Kotov et al., 
2017; Krueger, Caspi, Moffitt, & Silva, 1998; Slade & Watson, 2006; Vollebergh et al., 
2001). Notably, GAD is considered to be a part of the ‘anxious-misery’ cluster since it shares 
a more substantial portion of the general factor ‘negative affectivity’ variance compared to 
the other anxiety disorders, which are generally characterised by phobias and somatic arousal 
(Watson, 2005). Besides the fact that there are ongoing debates regarding the optimal 
placement of disorders within the lower arrangement, the broader domains are considered 
robust (de Jonge et al., 2018; Kotov et al., 2017) and likely account for the higher than 
chance comorbidity patterns observed across the lifespan (Kessler, Petukhova, & Zaslavsky, 
2011).    
Despite evidence that ‘anxious-misery’ and ‘fear’ disorders better predict health outcomes (in 
contrast to disorder-specific variations) (Eaton et al., 2013), this theoretical framework is 
rarely used to inform psychiatric screening procedures in health settings. Both the American 
Heart Association (AHA) and National Heart Foundation (NHF) of Australia recommend 
routine screening of depression, not anxiety, as an isolated pathway to clinical intervention 
(Colquhoun et al., 2013; Lichtman et al., 2008), undeterred by the well-known high rates of 
comorbid anxiety and depression in clinical and community samples (Brown et al., 2001). 
Further, since the release of that recommendation studies have shown that approximately 
50% of coronary heart disease persons have comorbid depression and anxiety (Tully, Cosh, 
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& Baumeister, 2014). Due to the spotlight now on the high prevalence of anxiety disorders in 
cardiovascular disease, studies are now attempting to improve its detection rate by reporting 
on the psychometrics of common anxiety screening tools (Bunevicius et al., 2013). However, 
given that comorbidity between disorders is the norm rather than the exception (Thibodeau et 
al., 2015), it is rarely appropriate to limit assessment of mental health to single disorders, and 
this can have dramatic implications for screening. Indeed, as reflected in the findings by 
Bunevicius and colleagues, disorder-specific screening omits a substantial number of persons 
that are potential candidates for intervention (Bunevicius, 2013). It could be argued that at the 
screening stages, enquires about single disorders are less meaningful when the primary goal 
is to detect clinically relevant psychological distress and streamline patients into clinical 
supports. Due to the high likelihood of comorbidity, the aforementioned emotional clusters 
may aid screening efforts in cardiovascular populations by targeting the common factors (i.e. 
‘anxious-misery’ or ‘fear’) that contribute to the depression and anxiety disorders.   
In addition, to date, interventions in cardiovascular disease have been almost exclusively 
limited to depression even though disorder-specific interventions pay relatively little attention 
to comorbidity. Fatigue, loss of energy and sleep disturbances have been shown to persist in 
coronary heart disease persons even when they no longer meet full diagnostic criteria for 
depression (Conradi, Ormel, & De Jonge, 2011). Interestingly, fatigability and sleep 
disturbances are also diagnostic features of GAD and the two disorders (e.g., Major 
Depression Disorder and GAD) frequently co-occur (Leventhal & Rehm, 2005). The 
‘anxious-misery’ and ‘fear’ clusters could enable a movement away from individual disorder 
based treatments to more transdiagnostic methods that allow clinicians to target common 
symptoms and processes that subsume the broader range of emotional disorders (Barlow et 
al., 2011). Promisingly, transdiagnostic treatments have been shown to better target comorbid 
symptoms (Norton et al., 2013), as opposed to single disorder treatments, possibly targeting 
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the fundamental features of emotional disorders (i.e., negative affectivity). Importantly, the 
low effect sizes present in randomised control trials (RCT) for depression in coronary heart 
disease samples underscores the importance of looking beyond depression to improve patient 
outcomes (Carney & Freedland, 2017). Sufficient evidence now exists to suggest that 
depression and anxiety in cardiac populations increase the risk of adverse cardiac outcomes 
independently, as well as some studies suggesting additive risk if two disorders are present 
(Doering et al., 2010; Phillips et al., 2009; Watkins et al., 2013). Therefore, there is no 
denying the clinical importance of improving screening and intervention efforts among 
cardiovascular populations.   
Few studies have employed psychiatric theory about the broader emotional clusters to inform 
screening procedures in a cardiovascular population (Tully & Penninx, 2012). Bearing in 
mind the limitations of the research above, the objective of the current study is to evaluate the 
screening utility and diagnostic detection of four common clinical tools for the screening of 
the emotional disorders in a cardiovascular population. The tools employed were the Patient 
Health Questionnaire- 9 item (PHQ-9) scale, Generalised Anxiety Disorder- 7 item (GAD-7) 
scale, Overall Anxiety Severity Impairment Scale (OASIS) and Depression Anxiety Stress 
Scale (DASS) – Stress subscale. Scores on the PHQ-9, GAD-7, OASIS, and the DASS-stress 
scale were used to detect the presence or absence of the theoretical groupings of ‘anxious-
misery’ and ‘fear’ disorders with receiver operating characteristics (ROCs), i.e. the true/false 
positive detection rates. As it remains unclear as to the optimal placement in this structure for 
several disorders including OCD (Cox, Clara, Hills, & Sareen, 2010; Prenoveau et al., 2010; 
Raines, Allan, Oglesby, Short, & Schmidt, 2015), GAD (Mennin, Heimberg, Fresco, & 
Ritter, 2008), and Panic Disorder (Greene & Eaton, 2016; Wright et al., 2013), different 
clusters forms will be explored.  
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The PHQ-9 and the GAD-7 were theorised to reflect the ‘anxious-misery’ cluster given their 
design was formulated to capture symptoms of depression and generalized anxiety, 
respectively. Given the OASIS is a measure capturing anxiety and fear, it was theorised to be 
more associated with the ‘fear’, rather than the ‘anxious-misery’ cluster. The DASS-stress 
was theorised to reflect both ‘anxious-misery’ and ‘fear’ clusters given it is relatively non-
specific (i.e., measures shared trait neuroticism, or, negative affectivity). We hypothesised 
that the PHQ-9 and the GAD-7 would be superior to the OASIS and the DASS-stress for the 
‘anxious-misery’ cluster and that the OASIS will be superior to the PHQ-9, GAD, and 
DASS-stress for the ‘fear’ cluster. It is hypothesised that the DASS-stress will be associated 
with both the ‘anxious-misery’ and ‘fear’ clusters.  
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Methods 
Design and Procedure  
This study presents a secondary analysis of a single-blind randomized control trial to evaluate 
the feasibility of a unified protocol for the transdiagnostic treatment of emotional disorders 
intervention in patients recently hospitalised for cardiovascular diseases. The Cardiovascular 
Health Anxiety Mood Problems Study (CHAMPS) (Tully et al., 2016) study is completed, 
and the Human Research Ethics Committee (HREC) from the Queen Elizabeth Hospital 
approved the study design (approval #HREC/15/TQEH47). The screening was a two-step 
process as recommended by the AHA to confirm elevated symptoms of anxiety and 
depression after hospitalisation. During the cardiovascular disease admission, each 
participant was screened with the PHQ-9 and the GAD-7 by an authorised hospital staff 
member employed as a trial manager in the cardiology department. All patients screening 
positive (PHQ-9 cut off >9 (Colquhoun et al., 2013), GAD-7 cut off  >6 (Kroenke, Spitzer, 
Williams, & Löwe, 2010)) were screened again approximately 1-2 weeks later with the PHQ-
9, GAD-7, OASIS, DASS-stress, and the MINI - International Neuropsychiatric Interview 
(MINI) to determine eligibility.   
Participants  
The participants in the trial were consenting patients with a primary hospital administration 
for cardiovascular disease to the Cardiology Department of the Queen Elizabeth Hospital. 
Inclusion criteria were: 18 years of age, proficiency in the English language, and had a 
primary hospital admission for a cardiovascular disease (specified by relevant International 
Classification of Disease codes for CAD, myocardial infarction, heart failure, atrial 
fibrillation, other ventricular or atrial arrhythmia, coronary revascularization intervention, 
symptomatic coronary heart disease including unstable angina pectoris, or heart valve 
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disease). Ineligible participants had a known or observed cognitive impairment or dementia, a 
medical condition likely to be fatal within one year, or a neurodegenerative condition such as 
Parkinson’s or Multiple Sclerosis. The trial further excluded n = 3 persons with substance or 
alcohol dependence/abuse and these participants were included in the current analyses on 
psychiatric screening in cardiovascular patients.  
Measures  
Psychiatric Diagnosis  
All participants were reviewed psychiatrically using a structured diagnostic interview 
(MINI) (Sheehan et al., 1998). The MINI served as the ‘gold standard’ and was performed 
blinded by study assessors to determine the presence of a primary psychiatric diagnosis 
(yes/no).  The MINI has high sensitivity and specificity to detect the emotional disorders, 
with Kappa coefficients (κ = .86 - .96) suggesting a favourable agreement with the Diagnostic 
and Statistical Manual of Mental Disorders-IV (DSM-IV). Participants were included in the 
‘anxious-misery’ cluster a if they met criteria for major depression disorder, dysthymia, GAD, 
post-traumatic stress disorder, and bi-polar disorder (Kotov et al., 2017; Watson, 2009). 
Participants were included in the fear cluster a if they met criteria for panic disorder, 
agoraphobia, social anxiety disorder, and OCD (Kotov et al., 2017; Watson, 2009). Given the 
debate about the optimal structure of the lower order emotional disorders (Kotov et al., 2017), 
the placement of disorders within clusters was investigated to assess their potential to inform 
screening procedures. The exploratory clusters were as follows: ‘anxious-misery’ cluster b - 
major depression, dysthymia, GAD, depression melancholic, post-traumatic stress, bi-polar, 
and OCD; ‘anxious-misery’ cluster c; major depression, dysthymia, generalized anxiety 
disorder, and depression melancholic; fear cluster b panic disorder, agoraphobia, social 
anxiety disorder, and post-traumatic stress disorder; fear cluster c; panic disorder, 
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agoraphobia, and social anxiety disorder. Notably, emotional disorder comorbidity prohibited 
participants from being exclusively related to only one of the clusters above.         
Self-reported Distress Scales  
The participants were administered the PHQ-9 item scale (Kroenke, Spitzer, & 
Williams, 2001), a standardised instrument that incorporates Diagnostic Statistical Manual -V 
depression criteria into a self-report tool to be used in primary care. Further, the PHQ-9 has 
been recommended by the AHA for screening in heart disease patients (Lichtman et al., 
2008). It is a reliable and well-validated scale where each item is scored from 0 to 3, totalling 
a maximum score of 27 (Kroenke et al., 2001). The participants were also administered the 
GAD-7 item scale (Spitzer, Kroenke, Williams, & Löwe, 2006). Participants scored on a 
scale of 0 to 3 (not at all, several days, more days than half the days, and nearly every day) 
how often in the last two weeks they were bothered by each symptom item. It does not 
contain any questions relating to somatic complaints and can distinguish between anxiety and 
depression making its use in cardiac populations appropriate. The GAD-7 is considered to be 
a psychometrically sound measure to use in primary care settings (Spitzer et al., 2006).  
In addition to the GAD-7 and PHQ-9, the OASIS and the DASS-stress were both 
administered. The OASIS (Norman, Hami Cissell, Means‐Christensen, & Stein, 2006) was 
developed as a self-report measure of anxiety that assesses multiple domains of clinical 
severity, including functional impairment, and captures the severity of any anxiety disorder 
(Campbell-sills et al., 2009). It is a short five-item scale that can be used as a continuous 
measure of anxiety-related severity and impairment. Participants respond to the items that 
best describe their experience on a five-point scale (0, little or none; 1, mild; 2, moderate; 3, 
severe; 4, extreme). The OASIS psychometric properties have been evaluated in primary care 
settings and are a valid instrument for measuring anxiety severity and impairment in clinical 
samples (Campbell-Sills et al., 2009). Stress was measured using the stress subscale of the 
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DASS (Brown, Chorpita, Korotitsch, & Barlow, 1997) a clinical measure used commonly, 
validated in adults aged to 90 years and in previous studies in cardiovascular populations 
(Tully, Baker, Knight, Turnbull, & Winefield, 2009; Tully, Baker, Turnbull, Winefield, & 
Knight, 2009).  Overall, there is limited knowledge of the PHQ-9, GAD-7, OASIS, and 
DASS-stress ROCs in cardiovascular populations. 
Statistical Analysis  
Statistical analysis was performed using MedCalc Statistical Software version, 18.5. The 
MINI affective diagnosis (yes/no) constituted the criterion standard for the presence or 
absence of cluster disorders. Scores on the screening measures (PHQ-9, GAD-7, OASIS, and 
DASS-stress), were used to detect clusters (arranged as ‘anxious-misery’ and ‘fear’ a, b, and c) 
from normal cases with ROCs, i.e., the true positive rate (sensitivity) plotted against the false 
positive rate (1-specificity) for all possible cut off points. The area under the curve (AUC), is 
the percentage of randomly drawn pairs for which the screening measures correctly classifies 
affected and non-affected cases and represents the diagnostic power of the test. An AUC of 
1.0 indicates the measure has perfect diagnostic properties, that is, all cases with the presence 
of a cluster disorder were detected by the measure, while those in the absence of a cluster 
disorder are correctly classified. An AUC of 0.5 indicates that the screening measure is no 
better than chance at detecting affective disorders or clusters. Interpretation of the AUC 
values were as follows: 0.5 - <0.7 mildly accurate, 0.7 – 0.9 moderately accurate, and 0.9 - 
<1 highly accurate. The screening measures cut off points were reported for AUC p <.05 and 
were determined by the maximal Youden Index (sensitivity + specificity – 100). The positive 
(PPV) (i.e. the likelihood that there is a cluster present given a positive test result) and the 
negative predictive value (NPV) (i.e. the likelihood that a cluster isn’t present given a 
negative test result) were also calculated. High sensitivity (i.e. a high false positive rate) at 
the expense of low specificity (i.e. a high false negative rate) also results in an inordinate 
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number of diagnostic interviews and therefore, a specificity of >75% is desirable for clinical 
purposes. The AUCs between measures were compared statistically using the methods of 
DeLong, DeLong, and Clarke-Pearson (1988). A p-value < 0.05 was considered as 
statistically significant, and no adjustment was made for multiple comparisons based on the 
recommendations of Rothman (1990). The rationale was that the study hypotheses are well 
defined, and secondly, that the study is exploratory in nature where the risk of Type II error is 
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Results 
A total of n = 85 patients were included and of those 59 (69.4%) were male (see Figure 1 
(Appendix A) for eligibility flowchart). In regards to CVD characteristics, 34.1% had angina 
pectoris, 25.9% had other ventricular or atrial arrhythmia, 25.9% had atrial fibrillation, 22.4% 
had coronary heart disease, 21.2% had a previous myocardial infarction (heart attack), 12.9% 
had acute myocardial infarction (heart attack), 10.6% had other symptomatic coronary heart 
disease, 9.4 % had heart valve disease, 8.2% had an implanted cardiac defibrillator, 5.9% had 
a biventricular pacemaker, and 3.5% had coronary artery disease.  Hypertension and 
Hypercholesterolemia were highly prevalent in 56 (65.9%), and 48 (56.5%) of the patients, 
respectively. In regards to psychiatric intervention, 4 (4.7%) were receiving antidepressant 
medical treatment, 2 (2.4%) had received counselling from a general practitioner, 1 (1.2%) 
was using anxiolytic medication, 1 (1.2%) was being treated by a psychiatrist, and no persons 
had been seen by a psychologist.      
----------------------------------------------------------------------------------------------------------------
INSERT FIGURE ONE ABOUT HERE (SEE APPENDIX A) 
---------------------------------------------------------------------------------------------------------------- 
The number of patients diagnosed with affective disorders on the MINI were as follows: 
major depression (n = 20, 23.5%), depression with melancholy (n = 11), GAD (n = 7, 8.2%), 
agoraphobia (n = 9, 10.6%), panic disorder (n = 6, 7.1%), bipolar (n = 4, 4.7%), social phobia 
(n = 2, 2.4%), post-traumatic stress disorder (n = 2, 2.4%), OCD (n = 1, 1.2%), and 
dysthymia (n = 0). Further, there were patients meeting criteria for alcohol dependence (n = 
3, 3.5%), and alcohol abuse (n = 1, 1.2%). In regards to comorbidity, the number of patients 
with comorbid affective disorders were as follows:  no disorder (57, 67.1%), one disorder 
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(12, 14.1%), two disorders (4, 4.7%), three disorders (7, 8.2%), four disorders (3, 3.5%), six 
disorders (1, 1.2%), and seven disorders (1, 1.2%).   
Area under the Curve (AUC) 
‘Anxious-misery’ cluster a. There were n = 21 (24.7%) persons meeting at least one 
diagnosis from the ‘anxious-misery’ cluster a (Note. Due to comorbidity between disorders 
the total number of depression, dysthymia, GAD, depression melancholic, post-traumatic 
stress disorder and bipolar surpasses 21). The ROCs are presented in Table 1. The AUC was 
greatest for the PHQ-9, followed by the GAD-7, the DASS-stress, and the OASIS. Using a 
cut-point of 6, the PHQ-9 showed favourable sensitivity (85.71%) and specificity (82.94%), 
while employing a cut point of 4 the GAD-7 yielded comparable sensitivity (85.71%) and 
specificity (82.81%). Employing a cut point of 2 the DASS-stress scale had a sensitivity of 
80.95%. However, a specificity of 58.81% and therefore, indicating suboptimal screening. 
The sensitivity of the OASIS was below 70%, also suggesting poor screening properties in 
detection of the ‘anxious-misery’ cluster a. Employing DeLong et al. (1988) methodology to 
compare the AUCs, the PHQ-9 (p = 0.049) and the GAD-7 (p = 0.048) had significantly 
higher AUCs than the OASIS. All other screening measures had comparable accuracy in 
detecting the ‘anxious-misery’ cluster a. Despite the DASS-stress scale indicating it is 
diagnostically comparable to the GAD-7 and the PHQ-9, its specificity values indicated 
otherwise (specificity, 57.81%).   
---------------------------------------------------------------------------------------------------------------- 
INSERT TABLE ONE ABOUT HERE (SEE APPENDIX B) 
---------------------------------------------------------------------------------------------------------------- 
‘Anxious-misery’ cluster b n = 21 (24.70%). The AUC was greatest for the PHQ-9. 
Employing a cut off of 7, the PHQ-9, again, showed desirable sensitivity (80.95%) and 
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specificity (94.12%), while the GAD-7 required a cut point of 4 for a sensitivity of 85.71% 
and specificity of 84.31%. The DASS-stress scale and the OASIS, again, demonstrated 
suboptimal screening properties in the detection of the ‘anxious-misery’ cluster b. Post hoc 
tests revealed that the GAD-7 (p = 0.031) and PHQ-9 (p = 0.031) AUCs were both 
statistically different from the OASIS highlighting the GAD-7 and PHQ-9 as more desirable 
for screening purposes. There were no other statistically discernible differences, and thus, 
again, the DASS stress-scale was considered to have a comparable diagnostic accuracy to the 
GAD-7 and PHQ-9. However, unlike the GAD-7 and PHQ-9, its specificity (62.75%) values 
yielded it diagnostically unfavourable.      
‘Anxious-misery’ cluster c n = 21 (24.70%). The AUC values in descending order 
were as follows: the PHQ-9, GAD-7, DASS-stress, and OASIS. Again, the PHQ-9 showed 
favourable sensitivity (85.71%) and specificity (82.94%), while employing a cut point of 4 
the GAD-7 also yielded a highly favourable sensitivity of 80.95% and a specificity of 
94.12%. When using a cut-point of 2, the DASS-stress scale had a sensitivity of 80.95%. 
However, its specificity (57.81%) was unfavourable. The OASIS also continued to show poor 
screening ability. The GAD-7 (p = 0.048) and PHQ-9 (p = 0.049) AUCs were statistically 
significant when compared to the AUC of the OASIS. Again, the DASS- stress scale was 
considered to have a comparable diagnostic accuracy to the GAD-7 and PHQ-9, despite 
unfavourable specificity values yielded by the DASS-stress (62.75%).  
Fear cluster a. n = 17 (21.52%). The AUC was greatest for the GAD-7 employing a 
cut off of 4 and favourable sensitivity (81.25%) and specificity (76.81%). A cut-off point of 7 
on the PHQ-9 showed a sensitivity of 68.75% and a specificity of 82.61% and therefore, 
considered unfavourable for screening purposes. Further, the OASIS and the DASS-stress 
yield matching sensitivity scores (75%) but, unfavourable specificity values (57.97% and 
53.62%, respectively). Employing DeLong, DeLong, and Clarke-Pearson methodology, the 
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GAD-7 was statistically significantly different from the DASS-stress scale (p = 0.046). The 
GAD-7 was the only measure to demonstrate suitable sensitivity and specificity values in this 
cluster. Further, there were no other statistically discernible differences between the AUCs 
indicating the other screening measures had comparable diagnostic accuracy. 
Fear cluster b n = 16 (18.82%). The AUC values in descending order were as follows: 
GAD-7, PHQ-9, OASIS, and DASS-stress. The GAD-7 was not statistically discernible from 
PHQ-9 or the OASIS, suggesting comparable diagnostic accuracy for detecting fear cluster b 
disorders. However, the GAD-7 was statistically different from the DASS-stress scale (p = 
0.027). Irrespective, the GAD-7 was not considered to be diagnostically more appropriate 
(sensitivity, 68.75%) There were no other statistically relevant differences, nor, did any of the 
sensitivity or specificity values indicate superior diagnostic qualities.      
Fear cluster c n = 15 (17.6%). Employing a cut-off of 7, the GAD-7 and the PHQ-9 
yielded unfavourable sensitivity scores (sensitivity, 66.67%), while the OASIS and the 
DASS-stress scale had specificity values considered to be suboptimal (specificity, <70). The 
GAD-7 was considered to be diagnostically more accurate than the DASS-stress scale in fear 
cluster c disorders (p = 0.024). Despite this finding, no measures in this cluster had suitable 
screening properties when evaluating the sensitivity and specificity values. Further, there 
were no other statistically discernible differences across measures.   
Sensitivity Analysis  
The main ROC analyses were repeated in sensitivity analyses using the primary 
formulation of ‘anxious-misery’ cluster a (n = 17, 21.52%), and ‘fear’ cluster a (n = 14, 
17.72%) excluding persons receiving current treatment. The ROCs are presented in Table 2. 
Similar findings were observed for detecting the ‘anxious-misery’ cluster. Employing a cut 
point of 7, with the PHQ-9 and GAD-7 revealed favourable sensitivity (82.35% and 70.59%, 
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respectively) and specificity (90.32% and 95.16%, respectively). The OASIS and the DASS-
stress scale yielded unfavourable values. The AUC for the PHQ-9 (p = 0.043) was 
significantly different from the DASS-stress scale indicating further screening benefits of the 
PHQ-9. There were no further statistically discernible differences between the AUCs in the 
‘anxious-misery’ cluster a, indicating comparable diagnostic accuracy. Employing a cut point 
of 4, the GAD-7 was the only screening measure from the ‘fear’ cluster a with favourable 
diagnostic qualities (sensitivity, 78.57%; specificity, 78.46%). Comparison of ROC curves 
did not yield any statistically significant differences between the screening measures 
suggesting similar screening accuracy across outcomes.     
---------------------------------------------------------------------------------------------------------------- 
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Discussion 
This study was particularly unique in its investigation of the emotional disorder clusters and 
their ability to inform screening procedures in cardiovascular disease populations. The ROC 
analysis supported the GAD-7 and the PHQ-9 for the screening of the ‘anxious-misery’ 
cluster, irrespective of cluster variations. While post hoc tests did not reveal any differences 
in the DASS-stress scales ability compared to the GAD-7 and the PHQ-9 to screen ‘anxious-
misery’ clusters indicating similar screening abilities, the specificity of the DASS-stress scale 
was unfavourable (specificity, <63%) when compared to the GAD-7 and the PHQ-9 
(specificities >85%). The OASIS also yielded unfavourable screening properties and 
therefore, as hypothesised, the PHQ-9 and GAD-7 were superior to the OASIS in all the 
‘anxious-misery’ clusters. Further, these results did not change for ‘anxious-misery’ cluster a 
in sensitivity analysis. The PHQ-9 and the GAD-7 also had high sensitivity and NPVs as 
compared to the other screening tools, with sensitivities above 80% and NPVs approximately 
95% or higher for the ‘anxious-misery’ clusters. Given that for screening purposes it is 
advantageous to attain high sensitivity and NPVs than high specificity and PPVs, the findings 
demonstrate that in the prediction of ‘anxious-misery’ disorders, the GAD-7 and PHQ-9 are 
effective for screening purposes in cardiovascular disease irrespective of the cluster 
variations.  
However, the PPV of the PHQ-9 was also high for ‘anxious-misery’ b cluster (77.5%) 
indicating that approximately three-quarters of the sample who had a positive result on the 
screening met the diagnostic criteria for one or more of the ‘anxious-misery’ cluster b 
disorders. These results are promising given the aim is to distinguish patients with clinically 
relevant disorders from those with more acute short-term distress.  Bunevicius et al. (2013) 
showed that the Hospital and Depression Scale-Anxiety (HADS-A), the Spielberger State-
Trait Anxiety Inventory (STAI), and the Spielberger State Anxiety Inventory (SSAI) for 
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anxiety disorder screening, yielded high false positive rates, indicating that their routine use 
would put excessive demands on healthcare resources. The high specificities and PPVs, and 
high sensitivities and NPVs of the PHQ-9 for the ‘anxious-misery’ cluster b, indicate that 
clinicians can be confident in excluding the presence of ‘anxious-misery’ cluster b disorders 
in respondents below recommended cut-points, and that patients who screen positive are 
likely to be clinically distressed and require clinical supports, despite lack of confirmation of 
a specific diagnosis.  
As the overall performance of the PHQ-9 and GAD-7 were remarkably similar in the 
‘anxious-misery’ clusters, the current findings suggest as single constructs identifying a 
‘anxious-misery’ cluster, either measure might be considered. One explanation for the 
similarities in screening properties is that the questions of the PHQ-9 and GAD-7 also cover 
some of the core symptoms of other ‘anxious-misery’ disorders. For example, the PHQ-9 
questions pertaining to restlessness, fatigue, difficulty concentrating, and sleep disturbances 
are similar symptoms experienced by other ‘anxious-misery’ disorders, while other common 
‘anxious-misery’ symptoms such as concentration difficulties, easily annoyed, irritable and 
agitation or restlessness are also covered by the GAD-7. Indeed, in a factor analytic study 
there were high correlations between PHQ-9 and GAD-7, and cross loading of GAD-7 items 
(e.g., trouble relaxing, restlessness and irritability) with the depression items. As a result, the 
researchers concluded that it is hard to differentiate between ‘anxious’ and ‘depressive’ 
distress (Böhnke, Lutz, & Delgadillo, 2014). The promising screening abilities of the PHQ-9 
and the GAD-7 to capture the ‘anxious-misery’ cluster may reflect a large extent the 
measures’ abilities to capture a single factor dimension, such as negative affectivity (Böhnke 
et al., 2014).  
The only diagnostically accurate tool for the ‘fear’ clusters was the GAD-7 yielding 
promising sensitivity (81.25%), and specificity (76.81%), but only in regards to ‘fear’ cluster 
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a (i.e. panic, agoraphobia, social anxiety, and OCD). Further, this did not change during 
sensitivity analysis. Recently, it was suggested that ‘worry’ may be best modelled at the 
broadest structural level, rather than an indicator of just ‘fear’ or ‘anxious-misery’ clusters 
(Naragon-Gainey, Prenoveau, Brown, & Zinbarg, 2016). This finding provides a worthy 
explanation for the ability of the GAD-7 to screen both ‘fear’ and ‘anxious-misery’ clusters 
(Naragon-Gainey et al., 2016). However, interestingly, the removal of OCD (n= 1) yielded 
screening inadequate for ‘fear’ cluster c. The increase in the sensitivity of ‘fear’ cluster a as a 
result of including OCD may simply be due to some overlap in the symptoms of OCD and 
those captured by the GAD-7 (e.g., feeling anxious or on edge, trouble relaxing, and feeling 
afraid something awful might happen). In addition, ‘worries’ can also be present in 
individuals with OCD (Abramowitz & Foa, 1998), and given their similarities ‘obsessions’ 
might be described by patients as ‘worries’ yielding the GAD-7 highly sensitive for 
individuals with OCD. A recent systematic review and meta-analysis indicated that further 
studies are still needed in primary care to determine if the GAD-7, a tool primarily 
formulated for GAD, is proficient in detecting other ‘fear’ disorders, including OCD 
(Plummer, Manea, Trepel, & McMillan, 2016).  
The finding that the OASIS screening properties were unfavourable for the ‘anxious-misery’ 
clusters was not surprising, given that the OASIS AUC is only considered ‘fair’, but not 
‘excellent’ at detecting the anxiety disorders it was designed for (Ito et al., 2015). Notably, 
none of those disorders was considered in the ‘anxious-misery’ cluster. Further, given that 
now the group of researchers have designed a scale to measure mood symptoms more 
specifically (i.e. Overall Depression Impairment Scale (ODIS); Bentley, Gallagher, Carl, & 
Barlow, 2014), this provides further evidence for the limitations of the OASIS in regards to 
the ‘anxious-misery’ cluster. An explanation for the low sensitivity (<55%) produced by the 
OASIS in the current study is that the measure was designed to tap the behavioural (i.e. 
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avoidance) and functional aspects (i.e. impairment in work, or, interpersonal relationships) of 
disorder severity, whereas the GAD-7 and PHQ-9 are likely affected by the frequency of 
cognitive-affective and/or somatic aspects of anxiety or depression (Ito et al., 2015). The 
symptoms experienced by heart disease patients might be different in that somatic/cognitive 
symptoms for the ‘anxious-misery’ cluster (e.g., feeling down, worry, irritability, poor 
concentration, and sleep problems) are a better predictor of clinical dysfunction, than 
avoidance or functional impairment.  
While avoidance is generally considered a hallmark of the ‘fear’ cluster (Mineka & Zinbarg, 
2006) and therefore, may explain the lack of sensitivity in predicting the ‘anxious-misery’ 
cluster, interestingly, the OASIS did not yield appropriate screening properties (specificity 
<60) for the ‘fear’ cluster, either. Consequently, the hypothesis that the OASIS would 
provide superior diagnostic qualities to the other measures in the ‘fear’ cluster was not 
supported. This was surprising given that the sample pertaining to the ‘fear’ cluster 
constituted agoraphobia, panic disorder, social anxiety disorder, and depending on the cluster 
variation, OCD, disorders whose hallmark is avoidance and associated functional impairment 
(Mineka & Zinbarg, 2006). In the current sample, the AUC was considered ‘mildly accurate’, 
and this is in line with previous research (Ito et al., 2015) reporting on the OASIS’ ability to 
detect ‘fear’ disorders (i.e. panic disorder, social anxiety disorder, and OCD)  
The hypotheses that the DASS-stress measure would be associated with both the ‘anxious-
misery’ and ‘fear’ clusters was partially supported. The AUC was considered to be ‘mildly’ 
accurate at detecting the ‘fear’ clusters and ‘moderately’ accurate at detecting the ‘anxious-
misery’ clusters. There is some debate over whether the DASS-stress measures a construct 
that is ‘similar’ to depression and anxiety (but not the same), since it nestles itself under the 
umbrella of the higher order negative affectivity factor, or, whether there are no discernible 
differences (Norton, 2007). Interestingly in the current study, the DASS-stress appeared to be 
         66 
 
more sensitive to the ‘anxious-misery’ cluster, than the ‘fear’ cluster (sensitivity, 80.95% vs. 
73.33-75%, respectively) indicating some differences in the way the DASS-stress performs in 
regards to the distinct clusters. An explanation for this could be that ‘stress’ and ‘worry’ 
might be intimately linked. For example, there is some evidence to suggest that individuals 
with non-clinical levels of ‘worry’ have been found to frequently and uncontrollably 
experience a high level of stress as measured by the DASS-stress (Szabó, 2011). Further, 
there is evidence that the DASS-stress scale can differentiate between patients with GAD and 
mood disorders from the other diagnostic groups (Brown et al., 1997).  
As mentioned earlier, recent research indicated that ‘worry’ more strongly loaded onto the 
general factor (i.e. negative affectivity) as opposed to the ‘fear’ or ‘anxious-misery’ clusters, 
and therefore, might be better modelled at the broadest structural level as a basic ‘emotional 
disorder’ (Brown, Chorpita, & Barlow, 1998; Naragon-Gainey et al., 2016). As mentioned 
above, if ‘worry’ and ‘stress’ are interlinked, then we might expect the DASS-stress to 
perform equally across clusters, however, this was not the case. An explanation for this is that 
GAD was included only in the ‘anxious-misery’ cluster and therefore, it was not considered 
as a ‘fear’ disorder. Given the close relationship speculated between GAD and the general 
factor (i.e. negative affectivity) (Naragon-Gainey et al., 2016), we might expect the DASS-
stress scale to perform differently depending on the position of GAD within the cluster 
variations.    
Generally, the performance of the PHQ-9 and GAD-7 measures as compared to the MINI 
was as good as reported in prior studies utilising other depression and anxiety scales for 
screening purposes in coronary heart disease patients. For example, the Hospital Anxiety and 
Depression Scale (HADS), measured against any diagnosis of depression and anxiety from 
the Clinical Interview Schedule-Revised (CIS-R), sensitivities and specificities were 85.78%, 
and 82.55%, respectively, while the NPV was 97.63% (Palacios, Khondoker, Achilla, Tylee, 
         67 
 
& Hotopf, 2016), findings comparable to ours. More recently, the HADS was tested in acute 
coronary syndrome and CAD where screening properties were again comparable (sensitivity, 
83.8% and 83.1%, respectively and specificity, 80.3% and 86.3%, respectively) (Tesio et al., 
2017). Some researchers (Kroenke et al., 2016) have attempted to amalgamate the GAD-7 
and the PHQ-9 (i.e., Patient Health Questionnaire-Anxiety Depression Scale (PHQ-ADS)) as 
a measure of overall psychological distress when the former is complicated by varying levels 
of depressive and anxiety symptoms (Chilcot et al., 2018). The findings here suggest that the 
clustering of highly comorbid disorders may eliminate the need for the bundling of already 
proficient screeners to create larger psychological batteries that are more time consuming for 
clinicians.  
While the AHA recommends routine screening of depression in cardiac populations 
(Lichtman et al., 2008), this guideline is challenged due to the paucity of evidence that 
systematic screening for depression is helpful to improve the outcome of coronary heart 
disease patients (Lichtman et al., 2014; Thombs et al., 2012). An explanation for this could be 
the treatment of single diagnoses failing to represent the comorbidity and clinical complexity 
of patients in real-world settings (Barlow et al., 2017). This study increases the breadth of 
screening to include anxiety disorders, which commonly co-occur with depression (Kessler et 
al., 2012), and which are important to recognise due to the substantial influence they can have 
on mental and physical health in this at-risk cohort (Celano, Suarez, Mastromauro, Januzzi, & 
Huffman, 2013). Cluster screening has the power to increase identification of comorbid 
emotional disorders that when undetected may reduce the efficacy of treatment on the other 
(Celano et al., 2012). Comorbidity of anxiety and depression is now the rule rather than the 
exception (Spinhoven, van Balkom, & Nolen, 2011) highlighting the problems with single 
disorder treatment protocols. Cluster screening accommodates highly comorbid emotional 
disorders and may improve patient treatment outcomes with the employment of 
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transdiagnostic interventions. In comparison to disorder-specific treatments, there is some 
evidence that transdiagnostic treatments are as effective for reducing anxiety, and may be 
superior for reducing depression (Newby, McKinnon, Kuyken, Gilbody, & Dalgleish, 2015). 
A large-scale Cochrane review also demonstrated the efficacy of interdisciplinary 
interventions. Specifically, they found that decreases in anxiety and depression were found 
with patients receiving collaborative care for up to two years compared to routine care 
(Archer et al., 2012). These findings indicate sufficient evidence to suggest that patients 
might benefit from emotional disorder screening in the context of an interdisciplinary 
treatment approach (McGuire, Emanuela, & Doering, 2015).  
Limitations and Future Directions  
The results of this study should be interpreted recognising several limitations including that 
the hierarchical structure of mental disorders is still debated in the literature (Beesdo‐baum et 
al., 2009) and not always supported (Conway & Brown, 2018). This debate and uncertainty 
are partly reflected in the number of structural models tested here, and therefore, 
interpretation of the ROCs utility for screening is tied to the validity of such disorder 
structures. Further, the current study did not include the externalizing disorder cluster (e.g., 
substance abuse and antisocial behaviour; (Kotov et al., 2017)) (Forbes et al., 2017). Since 
clinical trials in cardiovascular populations typically exclude patients with externalizing 
disorders, the significance of this group, including prevalence and prognosis of such disorders 
are lesser known. Concerning the sample, the MINI utilises hierarchical exclusion rules 
which may lower comorbidity rates and thus, resulted in no dysthymia cases in this sample. 
Given that there was also a small number of OCD, PTSD and bipolar disorder diagnoses in 
the current study, further investigation in diverse and larger samples of cardiovascular 
patients is justified to reproduce the current findings. Further, though this sample was derived 
from a cardiac in-patient ward, it is possible that some persons were without true 
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cardiovascular disease, given the known association between panic disorder and 
cardiovascular symptoms which frequently results in a misdiagnosis. Concerning the 
measures, older populations, low socio-economic, diverse ethnicities, and indigenous 
populations are also over-represented in cardiovascular settings, therefore, such 
psychological batteries may not be appropriate for all presenting patients (e.g., may have had 
trouble understanding the content of self-report questionnaires). The timing of the assessment 
(e.g., during or near an index cardiovascular admission) also may spuriously inflate 
symptoms, particularly somatic symptoms that are commonly experienced during 
hospitalisation and partially overlap with some mental disorders. Future research using factor 
analysis might be valuable in cardiovascular patients who experience a high number of 
somatic symptoms. Lastly, this was a single-centre design from a public hospital and 
therefore, our results may not generalise to other private hospitals or geographic regions. In 
light of these limitations,to the best of our knowledge this was one of the first studies to 
connect psychiatric theory to cardiovascular research and therefore, there is strength in its 
novelty and individuality.  
Conclusions 
In summary, the GAD-7 and PHQ-9 self-report scales provide sufficient screening measures 
to identify the ‘anxious-misery’ cluster. The GAD-7 also provided acceptable screening 
properties for the ‘fear’ cluster. Given the high likelihood of comorbidity, health-care settings 
should be aware of the potential advantages of shifting from traditional psychiatric 
taxonomies to an emphasis on the commonality and unity of psychiatric disorders, 
particularly as it may evidently provide an opportunity to benefit screening procedures in 
high-risk cohorts. Cluster-based screening in a CVD groups may also be a fruitful approach 
to increase the efficacy of current mental health interventions with the use of transdiagnostic 
intervening methods. Given that this is one of the first studies to evaluate the potential 
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screening benefits of employing hierarchical theory in a cardiovascular population, future 
research should continue to validate the diagnostic utility of the clusters in this high-risk 
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Figure 1. Flowchart of the screening process to determine eligibility. PHQ-9, Patient Health 
Questionnaire 9 item scale; GAD-7, Generalized anxiety disorder 7 item scale; OASIS, Overall 
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APPENDIX C 
Table 1  
Receiver Operating Characteristics of Clusters and Depression and Anxiety screening 
measures 









Anxious-misery a (n = 21) 
GAD-7d  .856 (.060) .763-.923 4 85.71 82.81 68.53 55.5 95.9 
PHQ-9e  .873 (.058) .783-.935 6 85.71 85.94 71.65 66.7 94.8 
OASIS  .692 (0.72) .582-.787 2 52.38 84.37 36.75 52.4 84.4 
DASS  .732 (0.60) .625-.822 2 80.95 57.81 38.76 38.6 90.2 
Anxious-misery b (n = 21) 
GAD-7d  .860 (.060) .758-.930 4 85.71 84.31 70.03 57.5 95.8 
PHQ-9e  .879 (.057) .780-.944 7 80.95 94.12 75.07 77.5 95.2 
OASIS  .680 (.074) .560-.785 3 47.62 88.24 35.85 50.3 87.1 
DASS  .747 (.061) .631-.842 2 80.95 62.75 43.70 35.2 92.9 
Anxious-misery c (n = 21)  
GAD-7d  .856 (.060) .763-.923 4 85.71 82.81 68.53 55.5 95.9 
PHQ-9e  .873 (.058) .783-.935 6 85.71 85.94 71.65 60.4 96.0 
OASIS  .692 (.072) .582-.787 2 52.38 84.37 36.76 45.6 87.6 
DASS  .732 (.060) .625-.822 2 80.95 57.81 38.76 32.4 92.4 
Fear a (n=17) 
GAD-7f  .776 (.076) .673-.860 4 81.25 76.81 58.06 38.2 95.9 
PHQ-9  .719 (.082) .611-.811 7 68.75 82.61 51.36 41.1 93.7 
OASIS  .673 (.073) .563-.771 0 75.00 57.97 32.97 29.3 90.9 
DASS  .626 (.077) .474-.777 2 75.00 53.62 28.62 22.2 92.4 
Fear b (n = 16) 
GAD-7  .787 (.077) .684-.868 7 68.75 91.30 60.05 58.3 94.3 
PHQ-9  .732 (.084) .625-.823 7 68.75 82.61 51.36 41.1 93.7 
OASIS  .669 (.072) .559-.768 0 75.00 57.97 32.97 23.9 92.9 
DASS  .621 (.074) .510-.724 2 75.00 53.62 28.62 22.2 92.4 
Fear c (n = 15) 
GAD-7g  .768 (.080) .663-.852 7 66.67 90.00 56.67 54.1 93.9 
PHQ-9  .710 (.087) .601-.803 7 66.67 81.43 48.10 38.8 93.3 
OASIS  .642 (.074) .531-.743 0 73.33 57.14 30.48 23.2 92.4 
DASS  .592 (.075) .480-.698 2 73.33 52.86 26.19 21.5 91.8 
Note. AUC = area under the curve; CI = confidence interval; Sens = Sensitivity; Spec = specificity; NPV = 
negative predictive value; PPV = positive predictive value; SE = standard error, GAD-7 = Generalized Anxiety 
Disorder- 7 item scale, PHQ-9 = Patient Health Questionnaire 9 item scale, OASIS = Overall Anxiety Severity 
Impairment Scale, DASS = Depression Anxiety Stress Scale – Stress subscale  
Current psychiatric disorders were derived by a structured clinical interview with the MINI 
a Anxious-misery’ group comprises major depression, dysthymia, generalized anxiety disorder, depression 
melancholic, post-traumatic stress, and bi-polar; Fear disorders group comprises panic disorder, agoraphobia, 
social anxiety disorder, and obsessive-compulsive disorder  
b Anxious-misery’ group comprises major depression, dysthymia, generalized anxiety disorder, depression 
melancholic, bi-polar and obsessive-compulsive disorder; Fear disorders group comprises panic disorder, 
agoraphobia, social anxiety disorder, and post-traumatic stress disorder  
c ‘anxious-misery’ group comprises major depression, dysthymia, generalized anxiety disorder, and depression 
melancholic; ‘Fear’ disorders group comprises panic disorder, agoraphobia, and social anxiety disorder 
d – The GAD-7 was significantly different (p < .05) from the OASIS 
e – The PHQ-9 was significantly different (p < .05) from the OASIS  
f – The GAD-7 was significantly different (p < .05) from the DASS-stress  
g – The GAD-7 was significantly different (p < .05) from the DASS-stress   
 




Table 2  
Receiver Operating Characteristics of Clusters and Depression and Anxiety screening 
measures  













Anxious-miserya (n = 17) 
GAD-7  .836 (.719) .736-.910 7 70.59 95.16 65.75 78.5 92.8 
PHQ-9c  .856 (.070) .759-.925 7 82.35 90.32 72.68 68.0 95.3 
OASIS  .647 (.080) .531-.751 2 47.06 87.10 34.16 47.7 86.8 
DASS  .679 (.068) .565-.780 2 76.47 56.45 32.92 28.5 91.6 
Feara (n = 14) 
GAD-7  .762 (.084) .653-.851 4 78.57 78.46 57.03 39.2 95.4 
PHQ-9  .701 (.090) .588-.799 7 64.29 83.08 47.36 40.1 92.9 
OASIS  .675 (.077) .561-.776 0 71.43 61.54 32.97 24.7 92.4 
DASS  .605 (.081) .489-.713 2 71.43 53.85 25.27 21.5 91.4 
Note. AUC = area under the curve; CI = confidence interval; Sens = Sensitivity; Spec = specificity; NPV = 
negative predictive value; PPV = positive predictive value; SE = standard error, GAD-7 = Generalized Anxiety 
Disorder- 7 item scale, PHQ-9 = Patient Health Questionnaire 9 item scale, OASIS = Overall Anxiety Severity 
Impairment Scale, DASS = Depression Anxiety Stress Scale – Stress subscale 
Current psychiatric disorders were derived by a structured clinical interview with the MINI  
a Anxious-misery group comprises major depression, dysthymia, GAD, depression melancholic, post-traumatic 
stress, and bi-polar; a Fear disorders group comprises panic disorders, agoraphobia, social anxiety disorder, 
and obsessive-compulsive disorder  
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Creative Commons license 
Open access articles are freely available to read, download and share from the time of 
publication under the terms of the Creative Commons License Attribution-NonCommerical 
No Derivative (CC BY-NC-ND) license. This license does not permit reuse for any 
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Permissions 
Authors must submit written permission from the copyright owner (usually the publisher) to 
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required by the copyright owner are the responsibility of the authors requesting use of the 
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Manuscript Submission  
Manuscripts that do not adhere to the following format requirements will not be reviewed. 
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at http://jnmd.edmgr.com. If the website is not available, contact Tara Hoey, Managing 
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First-time users: Please click the Register button from the menu and enter the requested 
information. On successful registration, you will be sent an e-mail indicating your user name 
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Registered authors: Please click the log-in button from the menu at the top of the page and 
log into the system as an Author. Submit your manuscript according to the author 
instructions. You will be able to track the progress of your manuscript through the system. If 
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Organization of Manuscripts 
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journal:Please also submit a separate document, using the "cover letter" option in the 
drop-down menu, that states the reasons it was rejected and what the authors have 
done to address these issues. If your manuscript has been submitted in any other 
version or form to any other publication please indicate this. 
2. Text file: A MS Word file without authors' names (to protect the peer review process). 
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